Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist
Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide, also known as LY3298176, has been excellent in reducing body weight and blood sugar in patients with poorly controlled Type 2 diabetes. Weight reduction has shown a positive effect in lowering NASH. Moreover, improvement of insulin sensitivity and lipid and fat metabolism can successfully improve NASH. The trials revealed that a higher dose in Tirzepatide lowers down the risk of liver disease at great extent. At present, NASH therapy market constitutes three drugs, ...
